Related content

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20, Iss. 1, 2018-01 ,pp. : 125-133

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia

By  

Current Drug Safety, Vol. 11, Iss. 2, 2016-04 ,pp. : 145-148

Bentham Science Publishers

Access to resources Recommend Favorite

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 3, 2015-03 ,pp. : 248-262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review

By  

AUSTRALIAN AND NEW ZEALAND JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol. 58, Iss. 1, 2018-02 ,pp. : 22-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Iron Deficiency in Heart Failure

By  

Cardiology, Vol. 128, Iss. 4, 2014-06 ,pp. : 317-319

Karger

Access to resources Recommend Favorite